Ann: Non-Executive Director retirement, page-10

These Donesta ( menopausal) trials have certainly
put a rocket under Mithra share price of late
Up 100+% in last 10 days. Mayne at this stage has no licensing or distribution agreements in hand with
Mithra existing.
Since we have Bijuva included in our last foray with TX
being a product with similar application I’m just
wondering what others may think of us taking on
to distribute in USA. Sho involved in uld it require anything like
the huge marketing cost overheads and rediculous
expenses to gain market share with Nextellis which
may succeed or yet may destroy the entire company
( who knows) but definitely $300 million plus so far
Mithr wouldn’t want to be trying to selk the same deal
with Donesta. I’m sure there would be a backlash.
Others opinion would be most welcome I would think.